Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855418 | 0.85 | ALDH1A1 (0.46) | CA1CA2CA4CA7CA9 | |
| SCHEMBL148818 | 0.75 | MAOA (0.42) | CA1CA2CA4CA7CA9 | |
| SCHEMBL29289768 | 0.73 | MAOB (0.58) | ALDH1A1GSTP1KDM4EMAPTHPGD | |
| SCHEMBL31098581 | 0.73 | MAOB (0.58) | ALDH1A1GSTP1KDM4EMAPTHPGD | |
| SCHEMBL15284506 | 0.71 | CA1 (0.38) | CA1CA2CA7CA9PDE3B | |
| SCHEMBL1162921 | 0.71 | NPC1 (0.41) | CA9ALDH1A1HTTLMNAHSD17B10 | |
| SCHEMBL31098477 | 0.71 | ESR2 (0.45) | CA1CA2CA7CA9TRPA1 | |
| SCHEMBL481795 | 0.71 | S100A4 (0.45) | CA1CA2CA4CA7CA9 | |
| SCHEMBL18939906 | 0.71 | — | — | |
| SCHEMBL3377831 | 0.71 | CA1 (0.52) | CA1CA2CA4CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| CN-115772156-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-08-06 | — | — | CN | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117736134-A | Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases | 耶鲁大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115772156-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20220402897-A1 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2814810-B1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2814810-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| WO-2013120835-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | CA1 3392/4885CA2 2385/4885CA4 2669/4885 |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | CA1 3498/4885CA2 2540/4885CA4 2992/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | CA1 4076/4885CA2 3113/4885CA4 3605/4885 |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | CYP11B2, CPT1A, SLC10A1 | CA1 3950/4885CA2 908/4885CA4 3016/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | CA1 4146/4885CA2 4709/4885CA4 2489/4885 |
| US-20220402897-A1 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HAVCR2, CYP7A1, CYP26B1 | CA1 4146/4885CA2 4709/4885CA4 2489/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | CA1 3108/4885CA2 3196/4885CA4 2981/4885 |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | CA1 2890/4885CA2 3215/4885CA4 3141/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | CA1 2360/4885CA2 1362/4885CA4 1527/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | CA1 2890/4885CA2 3215/4885CA4 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.